Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-10-27 Proxy Solicitation & In…
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
关于召开2025年第五次临时股东会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2025 fifth extraordinary general meeting (临时股东会) of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items to be discussed and voted on, registration procedures, and includes an authorization proxy form for shareholders to delegate voting rights. The document does not contain any financial statements, audit results, or detailed financial data. It is primarily an announcement informing shareholders about the meeting logistics and agenda, not the results or minutes of the meeting. The document length is 3238 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-10-27 Chinese
国浩律师（上海）事务所关于北京星昊医药股份有限公司2023年股权激励计划首次授予限制性股票第二个解除限售期解除限售条件成就、首次授予股票期权第二个行权期行权条件成就及回购注销部分限制性股票、注销部分股票期权相关事项的法律意见书
Board/Management Information Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding the 2023 equity incentive plan of Beijing Xinghao Pharmaceutical Co., Ltd. It discusses the granting of restricted stocks and stock options, conditions for lifting restrictions, repurchase and cancellation of shares, approvals by the board and supervisory committees, and compliance with relevant laws and regulations. The document includes detailed legal and procedural information about the equity incentive plan, approvals, and compliance, but it is not a financial report, earnings release, or regulatory announcement. It is a legal opinion related to management and governance matters concerning stock incentives and share repurchases. Therefore, the document best fits the category of Board/Management Information (MANG), as it relates to management decisions and board approvals on equity incentive plans and share cancellations.
2025-10-27 Chinese
关于部分限制性股票定向回购方案公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding a targeted repurchase plan of restricted stocks related to the company's 2023 equity incentive plan. It details the board meeting resolutions, the basis and type of repurchase, the number of shares to be repurchased and cancelled, the repurchase price adjustments, and the impact on the company's share capital and equity structure. It also includes management's analysis of the repurchase's impact on financial status and creditor protection measures. The document is a formal announcement of a share repurchase plan related to equity incentives, not a full financial report or earnings release. It is not a regulatory certification or a voting result announcement. The content fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares.
2025-10-27 Chinese
关于拟减少注册资本及修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding a proposed reduction in registered capital and amendments to the company's articles of association. It details the repurchase and cancellation of restricted shares due to employee departures and performance results, leading to a decrease in share capital. The document includes specific changes to the registered capital and share count, references relevant laws and stock exchange rules, and mentions that the amendments require shareholder approval. There is no financial statement or detailed financial report included, and the document is relatively short (1357 characters). This fits the profile of a Share Issue/Capital Change announcement, as it concerns changes in share capital and company capital structure. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2025-10-27 Chinese
薪酬与考核委员会关于2023年股权激励计划首次授予限制性股票第二个解除限售期解除限售条件、首次授予股票期权第二个行权期行权条件成就相关事项的核查意见
Remuneration Information Classification · 95% confidence The document is a formal announcement from the Compensation and Assessment Committee regarding the verification of conditions related to the company's 2023 equity incentive plan, specifically about the lifting of restrictions on restricted stock and the exercise conditions of stock options. It includes compliance statements with regulatory guidelines and confirms the legitimacy and fulfillment of conditions for the equity incentive plan. The document is short (912 characters) and focuses on remuneration and stock incentive matters, without containing financial statements or detailed financial data. It is not an annual report, earnings release, or management report. The content aligns with remuneration information disclosures about executive and employee compensation plans. Therefore, the document fits best under the Remuneration Information category (DEF 14A).
2025-10-27 Chinese
2025年第四次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2025 fourth extraordinary shareholders meeting of Beijing Xinghao Pharmaceutical Co., Ltd. It includes details about the meeting date, location, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the declaration of voting results for a specific shareholder meeting, including the approval of a capital increase and amendment of the company charter. The document length is short (1235 characters), and it is not a full report but an official announcement of voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-10-26 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.